NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications by Saskia M. Leibowitz & Jun Yan
REVIEW
published: 15 September 2016
doi: 10.3389/fnmol.2016.00084
NF-κB Pathways in the Pathogenesis
of Multiple Sclerosis and the
Therapeutic Implications
Saskia M. Leibowitz and Jun Yan*
UQ Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia
Edited by:
Marina Guizzetti,
Oregon Health & Science University,
USA
Reviewed by:
Nihar Ranjan Jana,
National Brain Research Centre, India
Ferdinando Nicoletti,
University of Catania, Italy
*Correspondence:
Jun Yan
j.yan@uq.edu.au
Received: 30 June 2016
Accepted: 29 August 2016
Published: 15 September 2016
Citation:
Leibowitz SM and Yan J (2016)
NF-κB Pathways in the Pathogenesis
of Multiple Sclerosis and the
Therapeutic Implications.
Front. Mol. Neurosci. 9:84.
doi: 10.3389/fnmol.2016.00084
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling
pathways are involved in cell immune responses, apoptosis and infections. In
multiple sclerosis (MS), NF-κB pathways are changed, leading to increased levels
of NF-κB activation in cells. This may indicate a key role for NF-κB in MS
pathogenesis. NF-κB signaling is complex, with many elements involved in its
activation and regulation. Interestingly, current MS treatments are found to be
directly or indirectly linked to NF-κB pathways and act to adjust the innate and
adaptive immune system in patients. In this review, we will first focus on the
intricacies of NF-κB signaling, including the activating pathways and regulatory
elements. Next, we will theorize about the role of NF-κB in MS pathogenesis,
based on current research findings, and discuss some of the associated therapeutic
implications. Lastly, we will review four new MS treatments which interrupt
NF-κB pathways—fingolimod, teriflunomide, dimethyl fumarate (DMF) and laquinimod
(LAQ)—and explain their mechanisms, and the possible strategy for MS treatments in
the future.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the human central
nervous system (CNS; Pender and Greer, 2007). MS causes vision, motor and sensory problems,
as well as a decline in cognitive, bladder and bowel function (Rudick et al., 1992; Yan and Greer,
2008).
MS pathogenesis has both genetic and environmental factors. Genes involved in immune
function have been shown to confer risk to MS, for example, the MHC class II allele HLA-DRB1∗15
(Miljkovic´ and Spasojevi c´, 2013) Furthermore, IL-2, IL-7 and CTLA-4 genes have also been linked
to MS (Miljkovic´ and Spasojevi c´, 2013). Low vitamin D levels have also been flagged as a possible
factor and may influence immune functioning (Miljkovic´ and Spasojevi c´, 2013). Another molecule
associated with immune functioning that has been implicated in MS pathogenesis is nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB).
Inflammatory and autoimmune diseases such as MS are associated with constitutive activation
of NF-κB which leads to excessive expression of the effector molecules whose transcription
relies on the NF-κB pathway (Li and Verma, 2002; Yamamoto and Gaynor, 2004). NF-κB
acts on many immune cells, producing effects that increase inflammation, as seen in MS
(Yan and Greer, 2008). NF-κB is crucial to the development, proliferation and survival of B and
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T lymphocytes and is involved in processes such as antibody class
switching, CD4+ T cell differentiation and cytokine production
(Yan and Greer, 2008). NF-κB also induces the production of
inflammatory mediators by dendritic cells, enhances antigen
processing and presentation in macrophages, and causes
production of pro-inflammatory cytokines and neurotoxic
mediators in microglia and astrocytes (Yan and Greer, 2008).
It is clear that excessive expression of NF-κB could promote
a pro-inflammatory milieu in which autoimmune diseases
could develop.
OVERVIEW OF NF-κB ACTIVATION
The mammalian NF-κB family is highly conserved and
comprises p65 (RelA), RelB, c-Rel, p50/p105 (NF-κB1) and
p52/p100 (NF-κB2; Zheng et al., 2011). These proteins all
possess a rel homology region (RHR) that consists of the
N-terminal domain (NTD), dimerization domain (DD)
and nuclear localization sequence (NLS; Huxford et al.,
2011). These domains allow dimerization (through DD),
DNA binding to target genes (through NTD and DD)
and nuclear translocation (through NLS; Huxford et al.,
2011). Alone, each member of the family is inactive in the
cytoplasm in the cells. The proteins assemble in various
combinations to form active homodimers and heterodimers
(Huxford et al., 2011). The NF-κB dimers interact with
specific sequence motifs known as κB sites on their target
genes and activate transcription (Zheng et al., 2011).
These κB sites show great variability, with each different
dimer combination having a distinct DNA-binding site
(Zheng et al., 2011).
The NF-κB proteins are tightly regulated by interactions
with the inhibitor of κB (IκB) family. These family members
possess an ankyrin repeat domain (ARD) that interacts with the
RHR, preventing the transcription factor from performing the
functions described previously (Zheng et al., 2011).
The IκB family consists of the classical IκBs (IκB-α, IκBβ and
IκBε), the NF-κB precursors (p105 and p100) and nuclear IκBs
(IκBζ, Bcl-3 and IκBNS; Malek et al., 1998, 2001; Zheng et al.,
2011). The classical IκBs inhibit p65, RelB and c-Rel and bind
dimers containing at least one p65 or c-Rel subunit (Zheng et al.,
2011). In contrast, p105 and p100 actually contain an IκB-like
domain that inhibits RHR (Zheng et al., 2011; Tao et al., 2014).
The nuclear IκBs bind p50 or p52 homodimer (Zheng et al.,
2011).
Certain stimuli, such as cytokines, chemokines, bacterial and
viral products, free radicals and UV radiation, can trigger NF-κB
activation (Yamamoto and Gaynor, 2004). There are at least
two NF-κB activation pathways that have been described: the
canonical and non-canonical pathways.
THE CANONICAL NF-κB SIGNALING
PATHWAY
The NF-κB canonical pathway is involved in gene activity
influencing cell biological processes in innate and adaptive
immunity, inflammation, stress, lymphoid organogenesis and B
cell development (Zhu et al., 2007). In the canonical pathway,
cells are stimulated by factors such as TNF-α, IL-1β and LPS
(Adhikari et al., 2007). Normally, NF-κB p65/p50 dimer is
bound to IκB-α — the inhibitor of NF-κB —and exists in the
cytoplasm in an inactive form (Phelps et al., 2000; Li and Verma,
2002). IκB proteins mask NLS on NF-κB subunits, causing the
NF-κB:IκB complex to remain in the cytoplasm (Li and Verma,
2002).
The canonical pathway can be initiated by TNF-α (see
Figure 1). Interestingly, levels of this cytokine have been
reported to be elevated in disease situations, including in MS
(Rentzos et al., 1996; Ozenci et al., 2000). When TNF-α interacts
with the TNF-R1 receptor, trimerization is initiated (Devin
et al., 2000). This trimerization leads to recruitment of TNF
receptor type 1-associated death domain protein (TRADD)
which in turn recruits TNF receptor-associated factor 2 (TRAF2)
and receptor-interacting protein 1 (RIP1; Devin et al., 2000).
TRAF2 is an E3 ubiquitin ligase that then mediates K63-linked
polyubiquitination of RIP1 (Adhikari et al., 2007; Spiegel and
Milstien, 2011). Compared to K48-linked polyubiquitination
which causes proteasomal degradation of target proteins, K63-
linked polyubiquitination allows RIP1 to recruit proteins (Spiegel
and Milstien, 2011). The polyubiquitinated RIP1 provides a
scaffold for the binding of TAB2 and NF-κB essential modulator
(NEMO), the regulatory unit of the IKK complex (Ea et al.,
2006). TAB2 recruits Transforming growth factor beta-activated
kinase 1 (TAK1) while NEMO and TRAF2 recruit the IKK
complex, comprising the IKKα and IKKβ subunits. TAK1,
which is rapidly activated after stimulation of cells with TNF-α
(as well as IL-1β, TLR and TCR) now in close proximity
with IKK, phosphorylates IKKβ, activating it (Wang et al.,
2001; Ea et al., 2006). IKKβ then can phosphorylate IκB-α
which is then ubiquitinated and degraded, releasing NF-κB
from the binding and allowing it to become the activated
form (Devin et al., 2000). NF-κB then can translocate into
the nucleus and bind to the promoter of genes to start gene
transcription.
IL-1β activates the NF-κB canonical pathway through a
MyD88-dependent pathway (see Figure 2). IL-1 receptors and
TLRs all possess a Toll/interleukin-1 receptor (TIR) domain
(Kawai and Akira, 2007). On receptor activation, through
homophilic interaction, the receptors recruit adaptor proteins
that also possess TIR domains (Kawai and Akira, 2007).
MyD88 comprises a TIR domain and is recruited. From
here, MyD88 interacts with IRAK1, IRAK2, IRAKM and
IRAK4 (Kawai and Akira, 2007). IRAK4 is activated first
and phosphorylates and activates IRAK1. IRAKM prevents
the dissociation of IRAK1 and IRAK4 from MyD88 (Kawai
and Akira, 2007). The function of IRAK2 is unknown. After
phosphorylation, IRAK1 and IRAK4 interact with TRAF6 which
causes self-ubiquitination as well as ubiquitination of NEMO
through Ubc13-Uev1a which are in complex with TRAF6
(Kawai and Akira, 2007). Ubiquitinated NEMO and TRAF6
then recruit TAK1 in complex with TABs1–3. The MAPK
pathway involving ERK is activated and this, along with TAK1,
activates IKKβ, leading to NF-κB release (Kawai and Akira,
2007).
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FIGURE 1 | The TNF-α-activated canonical nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. TNF-α triggers
TNF-R1 receptor trimerization. TNF receptor type 1-associated death domain protein (TRADD) is then recruited which, in turn, recruits TNF receptor-associated
factor 2 (TRAF2) and receptor-interacting protein 1 (RIP1). TRAF2 mediates K63-linked polyubiquitination of RIP1 which allows recruitment of TAB2 and NF-κB
essential modulator (NEMO). Following this, TAB2 recruits transforming growth factor beta-activated kinase 1 (TAK1) while NEMO and TRAF2 recruit the IKK
complex. TAK1 phosphorylates IKKβ which then phosphorylates IκB-α. IκB-α is then ubiquitinated and degraded, releasing NF-κB and allowing translocation into the
nucleus. P, phosphate; U, ubiquitin.
LPS binding to TLRs activates two primary pathways
downstream of TLR4 (see Figure 3). In the first pathway,
TIR-domain-containing adapter-inducing interferon-β (TRIF) is
recruited, and then recruits TRAF6 and RIP1 to the receptor
(Wertz and Dixit, 2010). The polyubiquitination of TRAF6 and
RIP1 facilitates TAK1 activation as described previously (Wertz
and Dixit, 2010). The second pathway is the MyD88 pathway as
described previously for IL-1β (Wertz and Dixit, 2010).
Another protein phosphorylated by IKKβ is the NF-κB
subunit p105, which is the precursor of NF-κB subunit p50
(see Figure 4). p105 is called NF-KB1 (Belich et al., 1999).
p105, like the other IκB family members, possessing an ARD,
acts as an inhibitor of not just p50 but also c-Rel and
RelA, retaining them in the cytoplasm and thus blocking
their transcription functions (Lang et al., 2003). In order to
release the inhibition, p105 must be proteolysed (Belich et al.,
1999; Gantke et al., 2011). IKKβ phosphorylation of p105
generates binding sites for ubiquitin ligases that then target
p105 for degradation (Lang et al., 2003) While there is a
basal level of constitutive, ubiquitin-independent processing that
occurs, this signal-dependent degradation of p105 accelerates
the process (Lang et al., 2003; Moorthy et al., 2006). As well
as inhibiting NF-κB translocation, p105 also exerts inhibitory
effects on tumor progression locus 2 (TPL2), a MAP 3 kinase
that is activated by TLR and TNF-αR stimulation (Gantke
et al., 2011). In steady state conditions, the entire pool of
TPL2 is associated with p105 but only a third of the p105
pool is occupied by TPL2 (DeCicco-Skinner, 2012). The target
of TPL2 phosphorylation is MEK which once activated, can
phosphorylate ERK (see Figure 4; Eliopoulos et al., 2002). This
is significant as ERK1/2 leads to increased TNF-α production,
increasing TNF-α-induced NF-κB production (van der Bruggen
et al., 1999). TNF-α itself can also activate ERK1/2 (Lebman and
Spiegel, 2008). In addition, ERK1/2 is suggested to play a role in
IKK activation, which also results in NF-κB production (Chen
and Lin, 2001).
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FIGURE 2 | The IL-1β-activated canonical NF-κB signaling pathway. The receptor is activated by IL-1β and recruits MyD88 through homophilic interactions
between toll/interleukin-1 receptor (TIR) domains. MyD88 interacts with IRAK1, IRAK2, IRAKM and IRAK4. IRAK4 is phosphorylated and then phosphorylates and
activates IRAK1. IRAK1 and IRAK4 interact with TRAF6 which self-ubiquitinates and also ubiquitinates NEMO through Ubc13-Uev1a, in complex with TRAF6. NEMO
and TRAF6 recruit TAK1 in complex with TABs1–3. TAK1, activates IKKβ, which then phosphorylates IκB-α. IκB-α is then ubiquitinated and degraded, releasing
NF-κB and allowing translocation into the nucleus. P, phosphate; U, ubiquitin.
Interestingly, p105 does not inhibit the catalytic activity
of TPL2, so it is possible that other targets of this molecule
are being phosphorylated, but being in complex with
p105 somehow prevents phosphorylation of MEK (Gantke
et al., 2011). Binding of TPL2 to MEK as well as the
ubiquitin-binding protein ABIN-2 offers stability to TPL2
(Gantke et al., 2011). The mechanism required to release
the inhibitory effect of p105 on TPL2 is the same as that
required to lift the inhibition on p50—proteolysis following
phosphorylation by IKK (Belich et al., 1999; Gantke et al.,
2011). Once p105 is degraded by the proteasome, TPL2 can
phosphorylate MEK (van der Bruggen et al., 1999; Gantke et al.,
2011).
TPL2 can also cause the production of TNF-α during
inflammatory responses (Gantke et al., 2011). In fact, the
TPL2/ERK pathway has been found to promote transport of the
TNF-αmRNA from the nucleus to the cytoplasm (Dumitru et al.,
2000). It has been found that blocking this pathway is sufficient
to inhibit the induction of TNF-α (Dumitru et al., 2000).
Other influences of TPL2 on the canonical pathway include its
interaction with TAK1, mediating responses to cytokines TNFα
or IL-1, through direct phosphorylation of IKK, leading to its
activation (Freudlsperger et al., 2013).
NON-CANONICAL NF-κB SIGNALING
PATHWAY
Activation of a subset of TNFR superfamily members including
BAFFR, CD40, LTbR, RANK and TNFR2, leads to activation
of NF-κB through the non-canonical pathway (see Figure 5;
Sun, 2011). Activation of these receptors all share a common
convergence on the activation of NF-κB-inducing kinase (NIK;
Sun, 2011). Normally, NIK is bound by TRAF3 which targets
it for constant ubiquitination and proteasomal degradation
(Sun, 2011). This occurs through the dimerization of TRAF3,
the adaptor molecule, with TRAF2, which can then allow
recruitment of the CIAP1/2 ubiquitin ligases (Sun, 2011;
Ersing et al., 2013). This complex ubiquitinates NIK for
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FIGURE 3 | The LPS-activated canonical NF-κB signaling pathways. (A) TIR-domain-containing adapter-inducing interferon-β (TRIF) is recruited to the TLR4
receptor. TRAF6 and RIP1 are then recruited. TRAF6 is polyubiquitinated and together with RIP1, the two proteins activate TAK1. (B) The MyD88 pathway as
described previously for IL-1β. P, phosphate; U, ubiquitin.
degradation. On ligand binding, receptors crosslink and the
TRAF2:TRAF3:CIAP1/2 complex is recruited via the association
between TRAF2 and TRAF3 and the TRAF-binding motif on
the receptors (Sun, 2011) TRAF2 then ubiquitinates cIAP1 and
cIAP2, which then ubiquitinate TRAF3 (and TRAF2 to some
extent) and stimulate its rapid degradation (Vallabhapurapu
et al., 2008; Ersing et al., 2013). NIK, now stabilized, reaches
a threshold concentration and auto-activates its kinase activity
(Ersing et al., 2013). NIK then phosphorylates and activates
IKKα (Sun, 2011). Unlike the canonical pathway where IKKβ
phosphorylates IκB-α, IKKα instead phosphorylates the NF-κB2
protein (Sun, 2011). The NF-κB2 gene, NF-κB2, encodes a
precursor protein p100 from which p52 is derived (Sun,
2011). NF-κB p100 possesses an ARD that masks the NLS on
p52. As mentioned, activation of TNFR superfamily members
culminates in activation of NIK, which activates IKKα. It is
proposed that formation of a NIK/IKKα/p100 complex may
be critical for subsequent p100 phosphorylation by IKKα
(Sun, 2011). Once phosphorylated, p100 is degraded by the
proteasome and p52 can dimerize and translocate to the
nucleus.
TPL2 is thought to play a role in the non-canonical pathway
too. The mechanism by which this occurs is thought to involve
IKK and NIK. TPL2 physically assembles with both these
proteins and TPL2, through its interaction with NIK, activates
NIK through phosphorylation (Lin et al., 1999; Eliopoulos et al.,
2002). In addition, studies show that ectopic expression of TPL2
activates IKKα, meaning TPL2 is one of three MAP3Ks that
can induce NF-κB through the IKKs, with the other two being
MEKK1 and NIK (Lin et al., 1999).
DEFECTIVE NF-κB SIGNALING PATHWAYS
IN MS
Many studies have found that NF-κB is activated in the
brain tissue of patients with MS. In actively demyelinating
plaques, there was increased nuclear localization of NF-κB
subunits in microglia, a subset of hypertrophic astrocytes and
lymphocytes (Gveric et al., 1998). Another study showed that
in active MS lesions, there was upregulation of nuclear NF-κB
in a large proportion of oligodendrocytes located at the edge
of active lesions and in microglia throughout plaques but
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FIGURE 4 | Canonical activation of p50. Once activated by normal canonical signaling, IKKβ phosphorylates NF-κB subunit p105, which is the precursor of
NF-κB subunit p50. Phosphorylation of p105 generates binding sites for ubiquitin ligases that then target p105 for degradation. p105 also inhibits tumor progression
locus 2 (TPL2) by binding with it. Once p105 is degraded, TPL2 is released and stabilized by binding to MEK and ABIN-2. TPL2 then phosphorylates MEK which
phosphorylates ERK, ERK1/2 leads to increased TNF-α production and can activate IKK. P, phosphate; U, ubiquitin.
not in healthy white matter or silent MS plaques (Bonetti
et al., 1999). Microarray analysis of MS brain tissue has also
identified upregulation of NF-κB itself as well as genes related
to NF-κB (Lock et al., 2002). One large study found that the
genes encoding NF-κB inhibitors exhibited significant sequence
variations (Miterski et al., 2002). In particular, they found
one predisposing allele in an IKBL gene and a protective
allele in the promoter of the IκB-α gene, NFKBIA, which was
decreased in frequency in primary progressive MS (Miterski
et al., 2002).
Variants have been identified within the NF-κB signaling
pathway in subjects with autoimmune diseases through genome-
wide association studies. In MS patients, variants near genes
involved in NF-κB signaling have been found and are functional,
potentially due to location in regulatory elements (Housley
et al., 2015). One such variant, proximal to NFKB1, increased
expression by twenty-fold (Housley et al., 2015). Another variant
was found in an intron of the TNFR1 gene, which led to increased
NF-κB signaling after TNF-α stimulation (Housley et al., 2015).
Both variants caused decreased expression of the negative
regulators of NF-κB, particularly IκB-α, through degradation
(Housley et al., 2015).
NF-κB IN MS PATHOGENESIS
The Role of Epstein–Barr Virus in
NF-κB-related Pathogenesis
NF-κB is associated with the pathogenesis of Epstein–Barr virus
(EBV)-derived MS. Studies have shown the crucial role of EBV
in the development of MS, with large studies showing that
MS patients are almost all seropositive for EBV (Lünemann
et al., 2007). There is a theory of molecular mimicry between
EBV- and CNS-derived epitopes (Lünemann et al., 2007).
EBV preferentially infects and transforms B lymphocytes by
inducing activation and continuous proliferation of these cells
(Lünemann et al., 2007). The transformed cells carry the viral
genome and express nine latent proteins (Allday, 2009). One of
these is LMP1, a membrane-bound signaling molecule (Allday,
2009).
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FIGURE 5 | Non-canonical NF-κB signaling pathway. (A) On ligand binding, receptors crosslink and the TRAF2:TRAF3:CIAP1/2 complex is recruited to the
receptors. TRAF2 ubiquitinates cIAP1 and cIAP2, which then ubiquitinate TRAF3 (and TRAF2 to some extent) and stimulate its rapid degradation. NF-κB-inducing
kinase (NIK) is released. TPL2 physically assembles with IKK and NIK and phosphorylates NIK which then phosphorylates and activates IKKα. TPL2 also activates
IKKα. IKKα phosphorylates p100. Once phosphorylated, p100 is degraded by the proteasome and p52 is released and can dimerize and translocate to the nucleus.
(B) Dimerization of TRAF3 with TRAF2 allows recruitment of the CIAPs1/2 ubiquitin ligases, Normally, NIK is bound by this complex and targeted for constant
ubiquitination and proteasomal degradation. P, phosphate; U, ubiquitin.
LMP1 has been found to constitutively activate NF-κB
through multiple mechanisms (Gewurz et al., 2011). First, LMP1
is an activator of the canonical pathway. LMP1 first activates
TRAF6 through interactions with adaptor proteins (Ersing et al.,
2013). A study suggests that the adaptor may be TRADD which
then recruits a TRAF2:TRAF6 heterodimer to the complex
(Schultheiss et al., 2001). TRAF6 then autoubiquitinates,
recruiting TAB2 and TAB3 and thus activating TAK1 as per usual
canonical signaling (Ersing et al., 2013). LMP1 also regulates
expression of target genes, and canonical NF-κB is a critical
component of this (Gewurz et al., 2011). LMP1 also activates
the non-canonical pathway. LMP1 recruits TRAFs 1, 2, 3 and
5 (Ersing et al., 2013). While the mechanism remains to be
elucidated, NIK is central to LMP1 induction on NF-κB activity.
It is probably through phosphorylation of NIK that LMP1
triggers activation of IKKα, leading to phosphorylation of p100
(Ersing et al., 2013).
LMP1 mimics CD40 leading to constitutive activation
of growth and survival pathways (Allday, 2009; Greenfeld
et al., 2015). CD40 is a member of the TNFR family and
has a motif to which TRAF2 can bind (Schultheiss et al.,
2001). LMP1 has been shown to induce TRAF1 which
heterodimerizes with TRAF2—LMP1 cannot mediate NF-κB
activation without TRAF2 (Devergne et al., 1996). In addition
to the intracellular signaling of LMP1, this protein can also
be released in exosomes to act in the microenvironment
(Lassmann et al., 2011). LMP1 has also been found to promote
the activation of TPL2 which has a major influence on
NF-κB signaling, as discussed previously (Eliopoulos et al.,
2002).
After primary EBV infection, the expression of most, if
not all, of the EBV latent proteins is down-regulated and a
lifelong reservoir of latently infected memory B cells exists
(Lassmann et al., 2011). These latent cells can be reactivated
by certain stimuli, including local inflammatory cytokines like
TNF, IL6 and CXCL13 (Lassmann et al., 2011). However, the
persistent antigen presence of EBV-infected B-blasts triggers a
robust T cell response that controls the events of reactivation
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(Hislop et al., 2005; Lünemann et al., 2007; Lassmann et al., 2011).
The mechanism may involve LMP1 as it can act on T cells and
studies have shown the responses are particularly TH1 polarized
leading to IFN-γ, TNF-α and IL-2 secretion (Sohn et al., 2015).
A recent study has found that in MS, there is a decreased
CD8+ T cell response to EBV (Pender et al., 2015). This was
proposed to be the result of a primary quantitative deficiency
in CD8+ T cells that may have a genetic background, as well as
superimposed T cell exhaustion from decreased CD4+ T cell help
(Pender et al., 2009, 2015). The deficiency in T cell immunity to
EBV-infected cells may allow accumulation of autoreactive EBV-
infected cells in the CNS and subsequent development of MS
(Pender et al., 2009).
As LMP1 causes constitutive NF-κB production, it would
be interesting to see if NF-κB has an effect on T cell
function. One study demonstrated that constitutive activation
of IKKβ, leading to constant production of NF-κB, as occurs
in certain chronic viral infections, caused T cells to be less
responsive to stimulation, triggered apoptosis and promoted
autoimmunity (Krishna et al., 2012). They observed that
these T cells resembled exhausted cells but were still able to
produce cytokines (Krishna et al., 2012). Exhausted T cells are
dysfunctional cells that arise during many chronic infections,
and are characterized by poor effector function and subsequent
deletion of antigen-specific T cells (Wherry, 2011). Therefore,
the link between EBV and MS may involve NF-κB production
through LMP1.
NF-κB-related Immune Responses in MS
and its Animal Model
Experimental autoimmune encephalomyelitis (EAE) is an acute
or chronic relapsing demyelinating disease that is used as
an experimental model of MS (Martin et al., 1995). It is
induced in susceptible animal strains by injection of myelin
or myelin components as well as adjuvants (Martin et al.,
1995). Subsequently, an autoimmune response ensues, mediated
by encephalitogenic T cells and the resultant demyelinating
lesions resemble those seen in MS (Martin et al., 1995). Like
MS, the pathogenesis of EAE is dependent on the activation
of pro-inflammatory mediators, many of which are under the
control of NF-κB (Pahan and Schmid, 2000). Hence, NF-κB
has been a major focus of studies into EAE pathogenesis
(Xie et al., 1994; Pahan and Schmid, 2000). The DNA-
binding activity of NF-κB, specifically the RelA/p65 and p50
subunits, was induced in EAE rat spinal cords only, with NF-κB
activation correlating with disease activity (Pahan and Schmid,
2000).
TH1 Responses in MS and EAE
NF-κB is known to be involved in TH1 responses and TH1 cells
are involved in MS and EAE pathogenesis (Mazzeo et al., 1998;
Becher and Segal, 2011). Serum levels of IL-12 were shown to be
higher in patients with secondary progressive MS compared with
controls and patients with other neurological diseases (Nicoletti
et al., 1996). IL-12 levels were also higher in progressive MS
compared with relapsing-remitting MS (Balashov et al., 1997).
IL-12 is responsible for the raised IFN-γ secretion known to
exacerbate MS, unlike in EAE, where IL-12 but not IFN-γ
exacerbated EAE (Panitch et al., 1987; Balashov et al., 1997;
Leonard et al., 1997; Segal et al., 1998).
T cells from MS patients induce IL-12 secretion from APCs
through a CD40-dependent mechanism that is initiated by TCR
engagement (Balashov et al., 1997). Subsequent signaling creates
a chronic activation of TH1 responses (Balashov et al., 1997).
Like IL-12 levels, which are higher in progressive MS, CD40
ligand-dependent TH1 activation occurred in the progressive but
not relapsing–remitting form of MS (Balashov et al., 1997). As
has been discussed, CD40 can activate the canonical and non-
canonical NF-κB pathways. Furthermore, there is evidence to
suggest that NF-κB is involved in IL-12 /p40 activation and IL-12
signaling (Murphy et al., 1995; Grohmann et al., 1998).
IL-18 augments the TH1 response as it can increase IFN-γ
expression in T cells and NK cells (Losy and Niezgoda,
2001; Karni et al., 2002). Antibodies against IL-18 block EAE
development (Wildbaum et al., 1998). In MS patients, IL-18
levels have been found to be increased in both serum and
CSF with levels being higher in secondary progressive MS
compared with relapsing-remitting MS, and higher in acute
exacerbations compared with stable disease (Losy and Niezgoda,
2001; Nicoletti et al., 2001). IL-18 depends on NF-κB for
signaling through MyD88 activation (Weinstock et al., 2003;
Alboni et al., 2010). NF-κB has also been shown to be
involved in IFN-γ expression, possibly through IL-12 and IL-18
(Sica et al., 1997).
IL-12 p70 is a heterodimer comprising p35 and p40 subunits.
Deficiencies in either p35 or p40 prevent production of IL-12
p70, but mice deficient in only p35 are still highly susceptible to
EAE (Becher and Segal, 2011). p40 knock-outs are resistant to
EAE (Segal et al., 1998). Interestingly, the p40 subunit combines
with a different factor, p19, to form IL-23 (Oppmann et al., 2000).
Moreover, it has been found that mice deficient in p19 (deficient
in IL-23) and p40 (deficient in IL-12 and IL-23) but not those
deficient in p35 (deficient in IL-12) were resistant to EAE (Cua
et al., 2003). Therefore, it was concluded that IL-23, not IL-12 is
the critical factor in EAE development (Cua et al., 2003).
TH17 Responses in MS and EAE
IL-23 activates macrophage production of pro-inflammatory
cytokines like IL-1 and TNF, cytokines which are known to
activate the NF-κB signaling pathway (Cua et al., 2003). IL-23
also induces TH17 cells (Sun et al., 2013). NF-κB is involved
in the induction of IL-23 in DCs and macrophages and has
been shown to be required for TH17 development (Cho et al.,
2006; Yang et al., 2008; Sun et al., 2013). TH17 cells have a
characteristic cytokine profile, comprising IL-17, IL-21, IL-22
and GM-CSF. This cellular subset has been implicated in
autoimmune inflammatory diseases such as MS. Patients with
MS have higher percentages of TH17 cells, higher expression
of IL-17 in cells near MS lesions and genetic linkage studies
have shown the IL-17 and IL-17R genes to be of interest in MS
(Matusevicius et al., 1999; Tzartos et al., 2008; Durelli et al., 2009;
Muls et al., 2012). EAE, like MS, is largely driven by a TH17
response.
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TH17 differentiation involves the retinoid-related orphan
receptor-γ (Rorg or Rorc) which is under control of c-Rel and
RelA (Ruan et al., 2011). Mice deficient in these NF-κB subunits
have compromised TH17 differentiation and responses (Yang
et al., 2008; Ruan et al., 2011). While RORγt-deficient mice
have marked TH17 impairment, deficiency does not completely
inhibit EAE development, while knock-out of RORα together
with RORγt, globally impaired TH17 responses with complete
protection from EAE (Yang et al., 2008).
IL-1β can also induce TH17 cells. In MS patients, the
expression of IL-1β, IL-1 receptor accessory protein and IL-1
receptor antagonist (IL-1Ra) are increased in CSF (Dujmovic
et al., 2009). Increased expression of IL-1Ra may seem
counterintuitive as this molecule inhibits IL-1 functions, but
it has been hypothesized to be part of a defense mechanism
that may be involved in MS remissions (Dujmovic et al., 2009).
Indeed, IL-1Ra administration leads to milder EAE signs than
controls (Badovinac et al., 1998). The ability of IL-1 to promote
IL-17 production by T cells has been shown to be dependent on
NF-κB signaling (Sutton et al., 2006).
To understand how TH17 cells mediate EAE, it is important
to elucidate the role of the effector cytokines produced
by this cellular population. IL-17 causes chemokine and
pro-inflammatory cytokine expression in astrocytes, which
leads to leukocyte recruitment during the induction of CNS
inflammation (Xiao et al., 2014). IL-17 mediates much of this
pro-inflammatory signaling through up-regulation of NF-κB.
IL-17 stimulation leads to the dissociation of TPL2 from
p105, allowing it to associate with TAK and influence NF-κB
production (Xiao et al., 2014). Indeed, TPL2 has been shown to
be a crucial mediator of EAE (Xiao et al., 2014). In addition, Act1
is an adaptor molecule that recruits TRAF6 to the IL-17 receptor
(Qu et al., 2012). Act1 mediates ubiquitination of TRAF6 which
subsequently autoubiquitinates. It is then suggested that TRAF6
follows the pathway as in LPS and IL-1β signaling to generate
NF-κB via the canonical pathway (Sønder et al., 2011). The onset
and severity of EAE was greatly reduced in Act1-deficient mice
(Kang et al., 2010).
However, while development of EAE is suppressed in IL-17-
deficient mice, with impaired T cell sensitization against myelin
antigens, it is not completely abolished (Komiyama et al., 2006).
Therefore, while both IL-17A and IL-17F are highly expressed
by encephalitogenic T cells, they may only marginally contribute
to EAE development (Haak et al., 2009). Hence, IL-23 promotes
EAE by IL-17 independent, as well as dependent, pathways
(Becher and Segal, 2011). Therefore, TH17 cells must produce
some other mediator of EAE.
TH17 cells also produce IL-21 and IL-22 (Becher and
Segal, 2011). However, EAE can develop in the absence of
IL-21 or IL-21R (Sonderegger et al., 2008). Furthermore,
IL-22 does not appear to be directly involved in EAE
(Kreymborg et al., 2007).
The Role of GM-CSF in MS and EAE
GM-CSF is the only known TH17 cytokine that is essential for
EAE as mice deficient in GM-CSF are resistant to EAE, with
decreased immune cell infiltration of the CNS (McQualter et al.,
2001; Becher and Segal, 2011). IL-23 stimulation and RORγt
drive expression of GM-CSF in T cells (Codarri et al., 2011).
It is proposed that RORγt only partially protects from EAE as
high homology of binding motifs shared with RORα allow it to
compensate for the absence of RORγt in GM-CSF expression (El-
Behi et al., 2011). Therefore, it follows that the double knockout
of RORγt and RORα would perturb GM-CSF expression more
fully, leading to complete protection from EAE. Both TH1
and TH17 subsets share the ability to up-regulate GM-CSF
(Codarri et al., 2011; Grifka-Walk et al., 2015; McWilliams et al.,
2015).
GM-CSF is crucial for the development of inflammatory
demyelinating lesions and for controlling migration and
proliferation of leukocytes within the CNS (McQualter et al.,
2001). GM-CSF production by T cells is greater in untreated MS
patients than healthy controls and IFN-β-treated MS patients,
suggesting that GM-CSF contributes to MS pathogenesis too
(Parajuli et al., 2012). GM-CSF has been shown to induce IL-23
in APCs which then induces GM-CSF expression by TH17 cells
(Ponomarev et al., 2007; El-Behi et al., 2011).
p52 and c-Rel have been implicated in the induction
of GM-CSF expression (Yu et al., 2014). It is proposed
that it is through the IL1R/MyD88/NF-κB pathway that
GM-CSF secretion by T cells and subsequent EAE are
induced (Sutton et al., 2006). Additionally, after it is activated,
GM-CSF has been shown to activate IKKβ, leading to IκB
degradation and further activation of NF-κB (Ebner et al.,
2003). Moreover, GM-CSF has been shown to increase
production of IL-1β, IL-6, TNF-α and NO by up-regulating
NF-κB (Parajuli et al., 2012). GM-CSF also up-regulates
ERK1/2 (Parajuli et al., 2012). Therefore, this highlights
that the pathogenic role of GM-CSF may relate to NF-κB
activation.
THE ROLE OF NF-κB INHIBITORS IN
DISEASE PATHOGENESIS
Delving further into the control of NF-κB signaling in TH17
responses requires discussion of the atypical IκB proteins,
a subset that includes IκBζ, IκBNS and BCL-3. The genes
encoding these proteins are actually regulated by NF-κB and
both positively and negatively modulate transcription by binding
to NF-κB transcription factors in the nucleus (Ghosh and
Hayden, 2008; Mankan et al., 2009; Schuster et al., 2012). The
significance of these proteins is that they add an additional layer
of control to NF-κB signaling. It is proposed that, depending
on the inducing receptor, different IκB family members may
be activated and may control NF-κB binding at specific gene
promoters, leading to differential gene expression (Touma et al.,
2007).
Of all the helper T cell subsets, IκBζ is most highly
expressed in TH17 cells and is induced by IL-17 (Okamoto
et al., 2010; Sønder et al., 2011). IκBζ up-regulates the
transcription of key inflammatory mediators including IL-6,
GM-CSF, G-CSF, IL-12p40, and IL-17, many of which are
involved in TH17 responses (Hildebrand et al., 2013). IκBζ
recruitment to the regulatory region of the IL-17 gene is
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dependent on the ROR nuclear receptors and IκBζ and the
ROR nuclear receptors act synergistically to increase IL-17
expression (Okamoto et al., 2010). IκBζ is a pro-inflammatory
mediator and positively regulates specific NF-κB-dependent
genes after LPS and IL-1 signaling, through the MyD88-
dependent signaling pathways (Ghosh and Hayden, 2008). It
associates with p50 homodimers that are bound to the IL-6
promoter, leading to IL-6 expression, a process that is abrogated
in deficient mice (Yamamoto et al., 2004; Ghosh and Hayden,
2008).
Like the ROR knock-out mice, IκBζ-deficient mice are also
resistant to TH17-dependent EAE (Okamoto et al., 2010). This
is possibly due to reduction in GM-CSF production, seeing as
IκBζ is involved in GM-CSF transcription. Furthermore, IκBζ-
deficient mice show decreased IL-17 production in the spleen and
lymph nodes, indicating a possible defect in TH17 development
(Okamoto et al., 2010). This results in a low sensitivity to EAE
with almost no neuronal deficit (Okamoto et al., 2010).
IκBNS is expressed during thymic natural T regulatory
(Treg) cell development, and is involved in Forkhead box
P3 positive (Foxp3) Treg induction through interactions with
p50 and c-Rel and upon TGF-β treatment (Schuster et al.,
2012). Foxp3 Treg cells are involved in maintaining peripheral
tolerance (Yamamoto et al., 2004). One study found that
mice deficient in IκBNS had a 50% reduction of mature
Treg cells (Schuster et al., 2012). In contrast, IκBζ does
not affect Treg cell development (Okamoto et al., 2010).
Interestingly, even though Treg numbers were severely reduced
in IκBNS-deficient mice, there were no signs of spontaneous
autoimmunity (Schuster et al., 2012). This points towards
potential involvement of IκBNS in the activation, proliferation,
or cytokine production of pro-inflammatory effector T cells
(Yamamoto et al., 2004). Indeed, IκBNS is involved in T cell
effector function, with one study highlighting that knockout
of IκBNS led to reduced IL-2 and IFN-γ production after
TCR triggering in CD8+ T cells (Touma et al., 2007).
Another study showed strongly impaired TH17 responses,
suggesting that IκBNS, like IκBζ, is also required for TH17
differentiation and function (Annemann et al., 2015). Therefore,
IκBNS acts differentially in Tregs and effector T cells as in
CD4+ TH cells it regulates proliferation and effector cytokine
production (Annemann et al., 2015). Furthermore, another
group concluded that IκBNS-deficient mice had decreased
expression of IL-17-related genes as well as RORγt in response
to TGF-β and IL-6 stimulation (Kobayashi et al., 2014).
Therefore, TH17 development was impacted and the deficient
mice were resistant to developing EAE (Kobayashi et al.,
2014).
THERAPEUTIC IMPLICATION OF NF-κB
INHIBITORS IN MS AND EAE
Inhibitors of NF-κB can be of multiple classes. Inhibitors
upstream of the IKK complex include: anti-TNF-α antibodies
or TNF receptor blockers; TRAF2 and TRAF6 mutants; and
MEKK1 and NIK mutants (Gilmore and Herscovitch, 2006).
Anti-TNF-α therapy has been shown to cause exacerbations of
MS (Titelbaum et al., 2005). Studies have found that TNF-α
exerts both pro-inflammatory and potent immunosuppressive
effects, explaining exacerbation of MS following anti-TNF
treatment (Kassiotis and Kollias, 2001). TNFR-1 is required
for noxious pro-inflammatory activities of TNF-α but not the
immunosuppression (Kassiotis and Kollias, 2001). TH1 and TH17
cells are activated through the TNFR-1 pathway while Tregs are
activated through the TNFR-2 pathway (Chen and Oppenheim,
2011). This suggests targeting the TNFR-1 pathway may be
beneficial in MS. Indeed, treatment of mice with a TNFR-1
blocker reduced the severity and onset of EAE and supressed TH1
and TH17 responses (Nomura et al., 2011). TRAF2 knockouts
skew towards TH17/TH1 responses so are not appropriate
(Lin et al., 2011b). TRAF3 negatively regulates IL-17 receptor
signaling and suppresses NF-κB activation (Zhu et al., 2010).
TRAF3 binding to IL-17R prevents the IL-17R–Act1–TRAF6
signaling activation complex from forming (Zhu et al., 2010).
Therefore, it is not surprising that TRAF3 attenuates EAE and
thus may be a therapeutic option (Zhu et al., 2010). Dominant
negative TRAF6 can block IL-17F-triggered ubiquitination
of IL-17R, preventing downstream signaling (Rong et al.,
2007).
It has been found that NIK-knockout mice are resistant
to EAE (Jin et al., 2009) While TH17 differentiation is
inhibited, NIK-deficient cells can commit to the other effector
lineages and thus NIK inhibition is specific (Jin et al., 2009).
Because NIK deficiency impairs TH17 development, all TH17-
derived inflammatory factors are impaired, leading to total EAE
resistance (Jin et al., 2009). NIK deficiency in T cells also impairs
effector function, with reduced IFN-γ expression (Jin et al.,
2009). A different study showed that NIK signaling is required for
DC secretion of T cell-instructive cytokines IL-12/IL-23p40 and
IL-16 (TH17 inducer), and its knockout caused EAE resistance
(Hofmann et al., 2011).
Inhibitors of IKK itself are another option. The mechanisms
include ATP analogs that have specificity for IKK, allosteric
inhibitors of IKK and compounds that interact with an activation
loop of IKKβ (Gupta et al., 2010). These inhibitors have a
200-fold preference for IKKβ compared with IKKα (Gupta
et al., 2010). There is evidence supporting the potential of
IKK inhibition with mice possessing inactive IKKα being
refractory to EAE and having defective TH17 cell differentiation
(Li et al., 2011). Similarly, IKKβ knockouts are completely
resistant to EAE (van Loo et al., 2006; Greve et al., 2007)
In addition, peptides that mimic the NEMO-binding domain
of IKK proteins can inhibit NF-κB as well as hinder T cell
effector function, leading to protection from EAE (Dasgupta
et al., 2004). Treatment of mice with IKK-inhibitory compound,
PS-1145, decreased disease severity when administered during
the induction of the disease (Greve et al., 2007). Inhibition
of IKKβ and NEMO in resident CNS cells interferes with
NF-κB and ameliorates EAE in mice (van Loo et al.,
2006).
Other inhibitors downstream of IKK include activators of
protein phosphatases, proteasome inhibitors, IκB ubiquitination
blockers, NF-κB nuclear translocation inhibitors, p65 acetylation
inhibitors, methyltransferase inhibitors, DNA binding inhibitors,
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molecules that up-regulate IκB and IκB super-repressors (Gupta
et al., 2010). Proteasome inhibitors such as bortezomib (PS-341)
and PS-519 have been trialed in EAE. Both have been shown
to inhibit NF-κB activation, reduce pro-inflammatory T cell
response and ameliorate EAE (Vanderlugt et al., 2000; Fissolo
et al., 2008). It has been shown that degradation of IκB, the
inhibitor of RelA, is increased in EAE and by preventing
degradation of IκB with TPCK (a protease inhibitor), the
incidence of EAE was decreased, with less severe disease and
quicker recovery (Hwang et al., 2011). A mutant version
of IκB-α that is resistant to degradation has been shown
to cause reduced effector responses in T cells after TCR
stimulation (Aune et al., 1999). The frequency of a gene
polymorphism of the IκB-α gene promoter (−708–8bpins)
has been reported to be decreased in primary progressive
MS (Miterski et al., 2002). PDTC, which directly blocks p50
and p65, inhibits NF-κB activation and pro-inflammatory gene
expression in rat spinal cords and attenuates the clinical
symptoms of EAE (Liu et al., 1999; Pahan and Schmid,
2000).
As for which subunit of NF-κB to target, there is evidence
that c-Rel-deficient mice are resistant to EAE and that targeting
RelA can also lessen EAE severity (Chen et al., 2011; Hwang
et al., 2011). RelB signaling is more complicated as it can
act as both an activator and repressor of NF-κB-dependent
gene expression (Marienfeld et al., 2003). Some studies suggest
RelB inhibits TH17 responses through epigenetic changes at
the IL-17 locus that prevent RORγt binding and that RelB-
deficient mice have exacerbated EAE (Xiao et al., 2015). This
suggests a protective role for RelB in EAE. Another study has
found that Malt1, an NF-κB regulator, is a critical determinant
of the encephalitogenic potential of TH17 cells (Brüstle et al.,
2012). Malt1 deficiency leads to a failure to cleave RelB,
allowing it to act as a suppressor of canonical NF-κB signaling
(Brüstle et al., 2012). Furthermore, Malt1-deficient mice have
poor IL-17 and GM-CSF expression and are protected from
EAE (Brüstle et al., 2012). However, others note that RelB
is required for RORγt and RORα4 expression and T cell
differentiation into γδT cells, a population that constitutively
expresses the IL-23 receptor and produces IL-17, IL-21 and
IL-22 in response to IL-1β and IL-23 (Sutton et al., 2009;
Petermann et al., 2010; Powolny-Budnicka et al., 2011). This
cell population increases susceptibility to EAE and has been
found in increased levels in the brains of mice with EAE
(Sutton et al., 2009). Therefore the targeting of RelB is not
clear cut as of yet and a better understanding of its function is
required.
p50 may be a reasonable target. NF-κB1-deficient mice
are significantly resistant to EAE, possibly due to its roles in
activation and differentiation of autoreactive T cells (Hilliard
et al., 1999). A review speculates that the phenotype of NF-κB1-
knockout mice is complicated by the effects that loss of p105
has on the stability of the proteins with which it associates
(Beinke and Ley, 2004). TPL2 and ABIN-2 are severely
reduced in p105-knockouts and thus the TPL2–MEK–ERK
pathway is affected as well as the NF-κB pathway
(Beinke and Ley, 2004).
While NF-κB inhibition is appealing, certain mice knock-out
models such as RelA, IKK and NEMO, are embryonic lethal and
c-Rel and RelB knockouts show impaired immunity (Beg et al.,
1995; Köntgen et al., 1995; Weih et al., 1995; Li et al., 1999a,b;
Liou et al., 1999; Kim et al., 2003; Schmidt-Supprian et al., 2004).
The effects of various NF-κB knockout combinations have been
reviewed extensively and will not be further elaborated here, but
it is important to note that the concept of NF-κB inhibition is
complex and a greater understanding of the role of each subunit
and component of the NF-κB pathway is required in order
to develop appropriate targets for inhibition without impairing
cellular immunity and responses to infections (Gerondakis et al.,
2006).
Other possible NF-κB inhibitors include: antioxidants;
bacterial, fungal and viral proteins that inhibit NF-κB; anti-
inflammatory and immunosuppressive agents; and p53
induction, which has been shown to repress NF-κB (Gupta
et al., 2010).
Anti-inflammatory and immunosuppressive agents are
currently used in MS treatment. EAE can take various forms,
depending on the neuroantigen used to induce the EAE and
the rodent strain used (Donia et al., 2010). Lewis rat EAE is
monophasic and self-remitting, Swiss-Jackson Laboratories mice
and Dark Agouti rats have a relapsing and remitting EAE and
C57Bl/6 mice have a chronic progressive course (Donia et al.,
2010). Dexamethasone administration prophylactically and in
early disease effectively suppressed EAE development in all four
of these groups (Donia et al., 2010). The mechanism for this may
depend on NF-κB as its activation is hindered by dexamethasone
treatment of macrophages (Crinelli et al., 2000). IκB-α gene
transcription was increased and TNF-α expression decreased
after dexamethasone treatment (Crinelli et al., 2000). Therefore,
glucocorticoids induce IκB-α expression, preventing NF-κB
activation and thus inhibiting cytokine gene expression (Auphan
et al., 1995; Scheinman et al., 1995). Glucocorticoid receptors
can also interact with NF-κB proteins, and interfere with their
DNA binding (Ray and Prefontaine, 1994).
Interferon-β (IFN-β) treatment causes increased levels of
the protein tyrosine phosphatase SHP-1 in PBMCs, which
has a role in inhibiting cytokine signaling, pro-inflammatory
gene expression and CNS demyelination (Christophi et al.,
2009). IFN-β also decreases NF-κB and STAT6 activation while
increasing STAT1 activation (Christophi et al., 2009). SHP-1
inhibits NF-κB expression (Neznanov et al., 2004). Increased
SHP-1 has modest inhibitory effects on STAT1 activation
that is overcome by the direct activating effect of IFN-β
(Christophi et al., 2009). STAT1 expression is pro-inflammatory
and could be responsible for the side effects of IFN-β
(Christophi et al., 2009).
NEW MS THERAPIES RELATED TO NF-κB
SIGNALING PATHWAYS
Evidently, NF-κB plays a key role in MS development, through
many different signaling pathways. Each signaling pathway
has many influencers, some of which act in many of the
NF-κB signaling pathways, and others that are limited to
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only a few NF-κB signaling pathways. Modulating NF-κB
is clearly a reasonable target for therapeutic intervention.
However, whether direct inhibition of NF-κB is the best
mechanism remains to be elucidated. Inhibition of the
influencers on NF-κB signaling may be a better approach
as this can allow fine-tuning of NF-κB signaling and the
potential targeting of dysfunctional proteins, restoring the NF-κB
balance. Interestingly, four promising therapies, fingolimod,
teriflunomide, dimethyl fumarate (DMF) and laquinimod
(LAQ), all modulate NF-κB signaling in some way and with
encouraging clinical evidence, three of the four have already
gained FDA approval.
FINGOLIMOD
Fingolimod is a new oral therapy for MS. It is an analog
of sphingosine, a molecule that has been implicated as an
influencer of NF-κB signaling (see Figure 6). The starting
point of the normal pathway is the activation of the kinase
SPHK1 by numerous stimuli, notably pro-inflammatory
cytokines such as TNF-α, PDGF, VEGF and EGF, which
promote that translocation of SPHK1 to the plasma membrane
where it phosphorylates sphingosine to form sphingosine-1
phosphate (S1P; Lebman and Spiegel, 2008; Colombo
et al., 2014). S1P acts on the S1P receptors S1P1-S1P5 in
an autocrine or paracrine manner (Spiegel and Milstien,
2011).
TNF-α is a potent activator of SPHK1 (Napolitano and Karin,
2010). When TRAF2 binds to the TNF-α receptor, it recruits
SPHK1 to induce the catalyzation of S1P formation (Napolitano
and Karin, 2010). Interestingly, S1P then acts as a cofactor for
TRAF2 and is essential for the TRAF2-mediated K63-linked
polyubiquitination of RIP1 (Napolitano and Karin, 2010).
S1P is also able to cause activation of ERK1/2 (Kim et al.,
2000). Both ERK2 and S1P further activate SPHK1, with ERK2
phosphorylation of SPHK1 increasing its affinity for the plasma
membrane (Takabe et al., 2008).
Putting this together, S1P is required for initiating the
canonical signaling pathway at an upstream position (through
TRAF2 and RIP), S1P activates ERK1/2 which leads to
activation of IKK, an integral member of canonical signaling,
and ERK1/2 also leads to TNF-α production, increasing total
flow through the canonical pathway, culminating in increased
NF-κB production.
FIGURE 6 | Sphingosine signaling. (A) During canonical signaling, when TRAF2 binds to the TNF-α receptor, it recruits SPHK1. SPHK1 catalyzes S1P formation.
S1P then acts as a cofactor for TRAF2-mediated K63-linked polyubiquitination of RIP1. (B) S1P also activates ERK1/2 and these together further activate SPHK1.
ERK1/2 activation leads to activation of IKK and increased TNF-α production, increasing total flow through the canonical pathway. P, phosphate; U, ubiquitin.
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Fingolimod, the sphingosine analog, is rapidly
phosphorylated into its active form where it modulates S1P1,
S1P3, S1P4 and S1P5 receptors (Colombo et al., 2014). However,
unlike S1P, binding of fingolimod to the receptors causes their
internalization and degradation, thereby halting the signaling
processes that have been discussed and in turn, decreasing
NF-κB production and TNF-α signaling (Colombo et al., 2014).
Fingolimod also has been shown to attenuate IL-17 signaling
which has been discussed as a key player in NF-κB production
(Liao et al., 2007).
Fingolimod also affects lymphocyte migration. The S1P1
receptor is responsible for T cell migration and accumulation in
peripheral lymph nodes (Yopp et al., 2005). In the presence of
intact chemokine systems, T and B cells require S1P1 activity for
egress from lymphoid organs (Yopp et al., 2005). S1P requires
ABCB1 and ABCC1 multidrug lipid transports to access the
extracellular space and activate the S1P1 receptor (Honig et al.,
2003). CCR7 is expressed on T cells and its ligands, CCL21 and
CCL19, in the T zone stromal cells. S1P1 acts on the lymphocytes
to promote lymph node egress by overcoming retention signals
mediated by CCR7 (Pham et al., 2008). CXCR4 and CCR2 have
been found to follow the same pattern (Yopp et al., 2005).
The importance of the interference in sphingosine signaling is
multifactorial. Peripherally, fingolimod prevents the trafficking
of immune cells out of secondary lymphoid organs, thus
preventing their migration into the CNS where the autoimmune
attack on myelinated neurons occurs (Colombo et al., 2014).
Fingolimod is also suspected to be able to cross the blood
brain barrier and therefore can act centrally on astrocytes
(Colombo et al., 2014). It has been shown that activation of
the S1P pathway and the resultant NF-κB production activates
astrocytes to sustain scar formation, and release toxic mediators
that contribute to neuroinflammation and neurodegeneration,
leading to formation of MS lesions (Colombo et al., 2014).
Fingolimod has been shown to impair astrocyte activation
and thereby block neurodegeneration induced by astrocytes
(Colombo et al., 2014). It is hypothesized that fingolimod
exerts a neuroprotective effect through this hampering of
astrocyte responses but does not directly rescue neurons
(Colombo et al., 2014). However, Bridela and Lalivea (2014)
show that it may actually promote a reparative process in the
CNS.
TERIFLUNOMIDE
Teriflunomide is an active metabolite of leflunomide (LN),
which is an anti-rheumatic drug (Bridela and Lalivea, 2014).
It functions by inhibiting dihydroorotate dehydrogenase, a key
enzyme involved in the de novo pyrimidine synthesis pathway
that is used heavily by rapidly proliferating lymphocytes (Bridela
and Lalivea, 2014). This blockage leads to a cytostatic effect on
proliferating B and T cells (Warnke et al., 2009).
Interestingly, a second effect has been studied (Manna
and Aggarwal, 1999). A study found that LN blocked the
TNF-α induction of NF-κB in a dose-dependent way (Manna
and Aggarwal, 1999). The study surmised that LN blocks
the activation of NF-κB by other stimulants too (Manna and
Aggarwal, 1999). It was found that LN inhibits the TNF-
induced p56lck and MEK activation (Manna and Aggarwal,
1999). P56lck is involved in the activation of ERK signaling
and so is MEK, therefore, this drug also acts on the pathway
discussed previously to decrease NF-κB production (Li et al.,
2008).
Another study has found that at low concentrations, LN
inhibits proliferation of T cells by inhibiting pyrimidine
biosynthesis as it is reversed when uridine is replaced (Elder
et al., 1997). However, at higher concentrations, uridine no
longer reverses the inhibition of proliferation, suggesting another
pathway is operating at this concentration (Elder et al., 1997). It
is inferred that the mechanism at this dose is the inhibition of
protein tyrosine kinases JAK1 and JAK3 as well as p56lck, as IL-2
induced phosphorylation of JAK1 and JAK3 are reduced at this
concentration (Elder et al., 1997).
To understand this interaction, it is crucial to understand how
signaling through IL-2 is initiated. First, as IL-2 receptor does
not possess kinase activity, it must recruit JAK (Williams, 2011).
The β chain of the receptor binds to JAK1, p56lck and STAT
proteins (Williams, 2011). The Υ chain binds to JAK3 (Williams,
2011). Heterodimerization bringing the β and Υ chain into
proximity causes phosphorylation of JAK1 and p56lck by JAK3
and initiates the binding of the STAT proteins (Williams, 2011).
Activated p56lck then activates P13K and anti-apoptotic BCL-2
proteins (Williams, 2011). Thus an anti-apoptotic pathway is
initiated (Williams, 2011). So it is clear that inhibition of
p56lck or prevention of JAK3 phosphorylation would interfere
with the proliferation and activation of lymphocytes as well
as the production of cytokines (Warnke et al., 2009). It is
important to remember that the effects of IL-2 are initiated by
factors such as NF-κB so there is yet again interplay with this
pathway.
Another effect of teriflunomide is an interference with the
interaction between T cells and antigen-presenting cells (APC)
crucial for T cell immune responses (Zeyda et al., 2005). Whether
this is through the disturbance of cell adhesion molecules and
matrix metalloproteinase is not known (Warnke et al., 2009).
DIMETHYL FUMARATE
DMF is another therapy for treating MS. It acts through multiple
mechanisms: it stimulates an anti-inflammatory response via
a Nrf2-dependent antioxidant response pathway; it inhibits
NF-κB signaling in an Nrf2-independent way, leading to
decreased inflammatory cytokine production; and it interferes
with maturation and function of antigen-presenting cells with
deviation from TH1 and TH17 responses to a TH2 phenotype
(Gerdes et al., 2007; Gold et al., 2012b; Peng et al., 2012; Linker
and Gold, 2013; Gillard et al., 2015).
Reactive oxygen species are thought to play a role in MS
pathogenesis. Reactive oxygen species activate NF-κB, leading
to the production of cytokines such as TNF-α and IL-12
(Nicholas et al., 2014). The ability of MS patients to cope
with oxidative stress appears to be diminished as evidence by
decreased glutathione (GSH) in the CSF: GSH is a key detoxifier
of free radicals and exogenous toxins (Peterson et al., 1998;
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Calabrese et al., 2003; Nicholas et al., 2014). It is theorized
that low levels of oxidative stress lead to a cellular antioxidant
response through Nrf2-mediated phase II enzyme expression
(Kim et al., 2007). At higher levels of stress, MAPK and NF-κB are
activated, exacerbating the pro-inflammatory effects (Kim et al.,
2007). At the highest levels of stress, apoptosis occurs (Kim et al.,
2007).
The internal GSH state in antigen presenting cells has been
found to be a crucial regulator of the immune response (Kim
et al., 2007). It has been found that when GSH levels are depleted,
TH2 responses are favored. (Kim et al., 2007) This response is
characterized by IL-4 and IL-10 as well as antibody responses
and has a significant anti-inflammatory, repair-orientated effect
(Peterson et al., 1998). In contrast, repletion of GSH skews the
immune response towards that of a TH1 response, leading to
IFN-γ and IL-12 production (Peterson et al., 1998; Kim et al.,
2007). Leukocytes are especially sensitive to these GSH changes
(Kim et al., 2007).
The importance of this phenomenon becomes clear when
discussing DMF. This molecule induces initial GSH depletion,
purportedly through formation of a stable complex (Schmidt
and Dringen, 2010). The depletion in GSH leads to expression
of hemoxygenase-1 (HO-1), which has been confirmed to be
upregulated after administration of DMF (Ghoreschi et al.,
2011). HO-1 acts as an anti-inflammatory and antioxidant
molecule and protects cells by inhibiting several immune effector
functions(Lehmann et al., 2007). One way in which HO-1
has been proposed to generate an anti-inflammatory milieu is
through modulation of cytokine expression. HO-1 has been
found to inhibit IL-12 and IFN-γ through DMF in immune
cells (Lehmann et al., 2007). Additionally, upon activation, HO-1
is cleaved and translocates to the nucleus where it interacts
with the IL-23p19 promoter in the NF-κB site and prevents
transcription of IL-23 (Ghoreschi et al., 2011). Taken together,
this provides evidence that HO-1 could mediate a shift from
a TH1/TH17 response, favoring production of IL-12, IL-23 and
IFN-γ, towards a TH2 response that generates Il-4, due to
initiation by type 2 dendritic cells that produce IL-10 (Ghoreschi
et al., 2011). Indeed studies show HO-1 plays a protective
role in EAE and deficiency of HO-1 leads to an exaggerated
inflammatory response (Nicholas et al., 2014). Interestingly,
expression of HO-1 is reduced in PBMCs of MS patients,
especially during disease exacerbation (Fagone et al., 2013). HO-
1 produces carbon monoxide (CO) as a by-product of heme
catabolism and thus is a carbon monoxide-releasing molecule
(CORM; Fagone et al., 2012). CORMs can create a controlled
quantity of CO which may be effective in treating diseases of
immune dysregulation (Fagone et al., 2012). HO-1 has been
shown to be protective in EAE models and CO administration
had similar effects (Chora et al., 2007) Endogenous HO-1 and
CO may be protective in EAE and MS and these could represent
a novel therapeutic option for MS (Fagone et al., 2012).
In addition, DMF impairs STAT1 phosphorylation, thereby
preventing IL-12p35 transcription. This was confirmed in
another study, where DMF decreased production of IL-12 and Il-
6 (Peng et al., 2012). IL-12 leads to IFN-γ producing CD4+ cells
(TH1) while IL-6 without IL-12 leads to a TH17 differentiation
(Lovett-Racke et al., 2011). This provides further evidence of
the shift to the TH2 response and the induction of an anti-
inflammatory, antioxidant environment (Ghoreschi et al., 2011).
DMF has been shown to increase nuclear levels of another
antioxidant—Nrf2 (Lin et al., 2011a). Normally, Nrf2 is
sequestered in the cytosol and polyubiquitinated by KEAP1,
leading to constitutive degradation (Gillard et al., 2015).
Oxidative stress changes the interaction between Nrf2 and
KEAP1, leading to Nrf2 translocation to the nucleus where it can
transcribe antioxidant and detoxification genes (Scannevin et al.,
2012; Gillard et al., 2015). Related to this, DMF interacts with
KEAP1 and results in the stabilization of Nrf2 and translocation
to the nucleus where it can exert its antioxidant functions (Gillard
et al., 2015). Some of the genes induced by Nrf2 are GSH-related
enzymes, therefore, while there is an initial decrease in GSH
concentration (after 2 h), the GSH concentration is increased
after 24 h (Lin et al., 2011a).
Expression of MHC class II, CD80 and CD86 is also hampered
by DMF, creating an immature dendritic cell phenotype that
cannot activate IL-17- or IFN-γ-producing CD4+ T cells (Peng
et al., 2012). Interestingly, it was also found that GSH depletion
leads to inhibition of the LPS-induced expression of CD80, CD87
and CD54 expression on DCs which is under the control of
NF-κB (Kim et al., 2007). In addition, it is known that NF-κB is
required for the development of TH1 responses (Li and Verma,
2002). So, these findings raise the question of whether DMF
interferes with NF-κB signaling and through this, impairs DC
maturation and impairs TH1 responses.
DMF impairs NF-κB signaling through multiple mechanisms
(Peng et al., 2012; Gillard et al., 2015). DMF suppresses ERK1/2
which has been discussed previously as an initiator of NF-κB
signaling (Peng et al., 2012). DMF also suppresses MSK1 the
kinase downstream of ERK1/2 which is involved in regulation
of transcription. This is significant as MSK1 phosphorylates p65,
thereby increasing transcriptional activity; first, by stabilizing
p65, permitting nuclear localization; and second, by enhancing
binding to coactivators and basal transcription factors (McCoy
et al., 2005; Peng et al., 2012). MSK1 and NF-κB may form a
transcription complex in inflammatory conditions, dependent
on this phosphorylation by MSK1 and thus MSK1 is required
for NF-κB activation and subsequent transcription (Reber
et al., 2009). Therefore, an additional effect of DMF is the
reduction of p65 nuclear localization through prevention of
phosphorylation to stabilize the transcription factor (Peng et al.,
2012). DMF may further prevent NF-κB translocation through
the attenuation of IκB-α degradation (Lin et al., 2011a). Thus,
DMF modulates NF-κB signaling mechanisms and, perhaps
through hindering NF-κB, impacts DC maturation and cytokine
production.
DMF has also been shown to inhibit TNF-α-induced
expression of the adhesion molecules VCAM-1, ICAM-1 and
E-selectin (Vandermeeren et al., 1997). Their expression relies
on the activation of a cytokine-inducible enhancer in the
promoter of their genes and these enhancers all contain a NF-κB
responsive element (Vandermeeren et al., 1997). Indeed, it has
been shown that inhibiting NF-κB blocks TNF-α induction
of E-selectin, VCAM-1 and ICAM-1 (Read et al., 1995).
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Upregulation of these adhesion molecules on the endothelium,
promotes migration of leukocytes from blood vessels into
tissues (Vandermeeren et al., 1997). Therefore, DMF can
prevent leukocyte influx into the brain tissue and decrease
inflammation.
LAQUINIMOD
LAQ is a quinolone-3-carboxamide small molecule (Bridela and
Lalivea, 2014). LAQ can diffuse across the blood brain barrier
and so can target the CNS immunity (Bridela and Lalivea, 2014;
Kieseier, 2014).
Studies show that NF-κB activation in astrocytes is
involved in demyelination and that LAQ interferes with
NF-κB activation to prevent demyelination (Brück et al.,
2012). Many mechanisms have been proposed. One study
showed that LAQ treatment slows down the degradation
of IκB-α, leading to reduced nuclear translocation of p65
(Brück et al., 2012). A different group found that expression
of IKKβ and NEMO was decreased after incubation with
LAQ, leading to increased amount of IκB-α (Jolivel et al.,
2013). Another study found increased gene expression of the
NF-κB inhibitor NF-KBIE and suppression of BTRC which
increases ubiquitination of the inhibitor (Gurevich et al.,
2010).
Transcription of NF-κB-controlled genes, IL-1β, TNF-α,
MIP1b, CXCL9 (a TH1 chemokine involved in T cell trafficking),
LY9 (involved in lymphocyte activation) and ICAM (involved in
activation and extravasation of leukocytes), were reduced after
DC treatment with LAQ (Gurevich et al., 2010; Jolivel et al.,
2013). In addition, degradation of p100 was also impaired by
LAQ (Jolivel et al., 2013).
NF-κB is required for maturation of DCs, which in turn
induces T cell differentiation (Jolivel et al., 2013). Thus, blockage
of NF-κB by LAQ, creates an immature DC phenotype with
reduced ability to induce CD4+ T cell proliferation, pro-
inflammatory cytokine secretion, chemokine production and
consequent migration of monocytes as well as a decrease in
DC number (Haggiag et al., 2013). However, unlike the effects
of DMF, where CD86 and CD80 were down-regulated, LAQ
upregulates CD86 while not modulating CD80 (Jolivel et al.,
2013). This upregulation of CD86 on its own is thought
to promote a semi-mature differentiation-locked tolerogenic
DC phenotype (Jolivel et al., 2013). Indeed CD86 and not
CD80 is required for immune tolerance (Liu et al., 1999).
Tolerogenic DCs induce T cell apoptosis, anergy and regulatory
T cells (Tregs; Li and Shi, 2015). Not surprisingly then,
it has also been found that LAQ augmented the Treg cell
response leading to further anti-inflammatory effects (Haggiag
et al., 2013). It is important to note that ex vivo studies
did not replicate the increase in CD86 (Stasiolek et al.,
2015).
LAQ has also been shown to reduce the levels of TNF-α,
IFNα, CSCL10, IL-23p19 and IL-12 p35 while upregulating anti-
inflammatory cytokines TGFβ, IL-10 and IL-4 (Gurevich et al.,
2010; Brück et al., 2012; Kieseier, 2014). LAQ thereby modulates
APCs to increase the occurrence of the anti-inflammatory type II
monocyte, shifting from the pro-inflammatory TH1 phenotype
(Brück and Wegner, 2011; Haggiag et al., 2013).
Another effect of LAQ is to reduce the entry of pro-
inflammatory T cells into the CNS (Kieseier, 2014). The
mechanism is by proposed lowering of MMP9 which regulates
migration of monocytes into inflamed tissues (Kieseier, 2014).
In addition, one study surmised that LAQ also led to down-
regulation of VLA-4 which binds to VCAM1 (Kieseier, 2014).
This is significant as VLA-4, expressed by leukocytes, mediates
firm adhesion to activated endothelial cells of the blood-brain
barrier, leading to transmigration and is a target of the drug
natalizumab (Schwab et al., 2015). However, with natalizumab,
there are questions regarding whether the benefit of the drug
justifies the risk of progressive multifocal leukoencephalopathy,
so perhaps LAQ may be a safer alternative (Schwab et al.,
2015) The mechanism whereby this down-regulation occurs
is not known, but a study has shown that IL-4 suppresses
VLA-4 expression thus perhaps the ability of LAQ to induce
TH2 cells and IL-4 production influences VLA-4 expression
(Sasaki et al., 2009). However, a different study suggest that it
is not down-regulation of VLA-4, but lack of responsiveness
to CCL21, a chemokine trigger, that causes the decreased
adhesiveness of VLA-4 (Wegner et al., 2010). The authors
propose that it is the inhibitory effect of LAQ on IL-17
and IL-13, which normally increase VLA-4 responsiveness to
CCL21, that is the mechanism (Wegner et al., 2010). Secretion
of IL-17 is indeed decreased by LAQ (Brück and Wegner,
2011).
Constitutive nitric oxide synthase expression by astrocytes has
been implicated in the development of MS plaques through the
production of nitrite oxide and superoxide radicals, which can
cause damage to oligodendrocytes, myelin sheaths and axons
(Brück et al., 2012). Neuronal death in MS is mediated by NO,
and MMP-9 can also kill neurons (Mishra et al., 2014). The
JNK, AKT and 90RSK pathways can also generate neurotoxins
(Mishra et al., 2014). This is important as LAQ treatment
suppresses inducible STAT1, NOS, JNK, AKT, MMP and
90RSK, thereby preventing neurotoxin development (Schulze-
Topphoff et al., 2012; Mishra et al., 2014). Clinically, in a mouse
model of demyelination involving cuprizone-treated mice, LAQ
prevented demyelination as well as microglia activation, axonal
transections, reactive gliosis and oligondendroglial apoptosis
(Brück et al., 2012). Therefore, it is proposed that LAQ might
have a neuroprotective effect via microglia (Mishra et al., 2014).
CLINICAL DATA
Data from clinical trials comparing the new therapies to a placebo
group can be seen in Table 1. The trials indicate that these drugs
can significantly reduce the annualized relapse rate compared
to placebo, with fingolimod offering the greatest reduction.
These drugs can also halt disease progression, except for lower-
dose teriflunomide, which recorded no reduction in progression.
Fingolimod and LAQ were noted to protect from brain loss.
In addition, fingolimod, teriflunomide and DMF outperformed
LAQ in improvements in MRI indicators of disease progression.
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CONCLUSION
It is clear that in MS, the pro-inflammatory NF-κB signaling
pathways are out of balance. NF-κB contributes to MS
pathogenesis and could represent a target for therapeutic
intervention. The pre-clinical model, EAE, highlights the
potential of molecules inhibiting elements of the NF-κB signaling
pathway as therapeutic options. Furthermore, the four drugs
discussed in this review all modulate the NF-κB pathway in
some respect, albeit through different mechanisms. Researches
have been expressing that targeting elements of this pathway
is paramount to treating MS, but it is clear that systemic
blockage of NF-κB would be unsafe as NF-κB has different
effects in different cell types, some of which are protective, some
detrimental (Kabashima et al., 2004; Mc Guire et al., 2013).
NF-κB is also required for normal cell functions, and it is essential
for mounting proper immune responses (Kabashima et al., 2004).
Indeed, certain therapies that operate too far upstream of NF-κB
may have disastrous consequences and affect related signaling
pathways.
More targeted therapies will be required to redress the
signaling faults. As far as which molecule should be the target, it
is clear that MS is a multifactorial disease not dependent on only
one gene, or inciting insult. It is entirely possible that there are a
variety of aberrant genes present in MS patients that decrease the
functioning of any of the many kinases and molecules implicated
in the NF-κB signaling pathway. This begs the question as to
whether patients be genetically screened for variants associated
with NF-κB signaling, as this may identify patients amenable to
NF-κB or cytokine blockade (Kabashima et al., 2004).
Therefore, crucial to the treatment of MS in the future will be
individualized treatment, dependent on the fault in the signaling
pathway. Improved knowledge of the specific activities of NF-κB
and NF-κB regulatory mechanisms in controlling inflammatory
and protective responses in these different cell types in MS and
EAE is required to better understand the disease and possible
therapeutic targets.
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